Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) FCF Margin (2016 - 2025)

Avalo Therapeutics' FCF Margin history spans 11 years, with the latest figure at 24216.95% for Q4 2025.

  • For Q4 2025, FCF Margin fell 1638153.0% year-over-year to 24216.95%; the TTM value through Dec 2025 reached 87288.14%, down 7616433.0%, while the annual FY2025 figure was 87288.14%, 7616433.0% down from the prior year.
  • FCF Margin reached 24216.95% in Q4 2025 per AVTX's latest filing, down from 7835.42% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 37.67% in Q3 2022 to a low of 24216.95% in Q4 2025.
  • Average FCF Margin over 5 years is 4025.33%, with a median of 1714.77% recorded in 2023.
  • Peak YoY movement for FCF Margin: surged 737305bps in 2022, then plummeted -1638153bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 7812.79% in 2021, then soared by 94bps to 439.73% in 2022, then fell by -10bps to 484.41% in 2023, then crashed by -1518bps to 7835.42% in 2024, then crashed by -209bps to 24216.95% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's FCF Margin are 24216.95% (Q4 2025), 7835.42% (Q4 2024), and 4629.32% (Q3 2024).